{"entity":{"id":"phillip-kuo","kind":"person","name":"Phillip H. Kuo","aka":[],"tldr":"A nuclear medicine physician who helped write the eligibility scans used to select prostate cancer patients for the VISION trial of lutetium-177 PSMA-617, and who also sets national standards for brain PET scans used in Alzheimer's disease.","summary":"Phillip Kuo spent a decade as Chief of Nuclear Medicine at the University of Arizona before moving in 2024 to City of Hope Cancer Center in Duarte, California, where he is Division Chief of Nuclear Medicine and Director of Theranostics. He co-authored the explanation of the PSMA PET/CT selection criteria used in the pivotal VISION trial of 177Lu-PSMA-617, and has contributed to SNMMI appropriate-use-criteria panels for both PSMA PET and 177Lu-PSMA-617 radioligand therapy.\n\nHe also works in neurodegeneration imaging, serving on the Alzheimer's Association/SNMMI workgroup that issues updated appropriate use criteria for amyloid and tau PET, and as a co-author of the SNMMI/EANM procedure standard for brain FDG PET. This dual focus on prostate cancer theranostics and dementia imaging makes him one of relatively few nuclear medicine leaders bridging oncologic and neurologic molecular imaging standards.","asOf":"2026-09-22","links":[{"label":"City of Hope profile","url":"https://www.cityofhope.org/phillip-kuo"},{"label":"Why we did what we did, JNM 2022","url":"https://jnm.snmjournals.org/content/63/6/816"}],"tags":["PSMA","theranostics","brain PET","clinician"],"related":["vision","pluvicto","psma-pet","lu-177"],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor and Division Chief of Nuclear Medicine and Director of Theranostics, Department of Diagnostic Radiology, City of Hope Cancer Center (since 2024; previously Chief of Nuclear Medicine, University of Arizona, 2014-2024)","specialisms":["PSMA PET patient selection","amyloid and tau brain PET","appropriate use criteria"],"profiles":[{"label":"City of Hope profile","url":"https://www.cityofhope.org/phillip-kuo"}],"papers":[{"title":"Why We Did What We Did: PSMA-PET/CT Selection Criteria for the VISION Trial","journal":"Journal of Nuclear Medicine","year":2022,"doi":"10.2967/jnumed.121.263638"},{"title":"Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup","journal":"Journal of Nuclear Medicine","year":2025,"doi":"10.2967/jnumed.124.268756"},{"title":"SNMMI Procedure Standard/EANM Practice Guideline for Brain [18F]FDG PET Imaging, Version 2.0","journal":"Journal of Nuclear Medicine","year":2025}]},"route":"/people/phillip-kuo/","neighbours":{"trial":[{"id":"vision","kind":"trial","name":"VISION","route":"/trials/vision/"}],"drug":[{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/"}],"technology":[{"id":"psma-pet","kind":"technology","name":"PSMA PET","route":"/technologies/psma-pet/"}],"isotope":[{"id":"lu-177","kind":"isotope","name":"Lutetium-177","route":"/isotopes/lu-177/"}]}}